Paller, C., Zahurek, M., Mandl, A., Rudek, M., Heath, E., Marshall, C. H., … Levine, M. (2023). 1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial. In Annals of Oncology (Vol. 34, pp. S992–S992). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2781

Paller, C., M. Zahurek, A. Mandl, M. Rudek, E. Heath, C. H. Marshall, M. C. Markowski, et al. “1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial.” In Annals of Oncology, 34:S992–S992. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2781.

Paller C, Zahurek M, Mandl A, Rudek M, Heath E, Marshall CH, et al. 1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial. In: Annals of Oncology. Elsevier BV; 2023. p. S992–S992.

Paller, C., et al. “1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S992–S992. Crossref, doi:10.1016/j.annonc.2023.09.2781.

Paller C, Zahurek M, Mandl A, Rudek M, Heath E, Marshall CH, Markowski MC, Lalji A, Metri N, Hoimes CJ, Taksey J, Durham J, Kelly W, Antonarakis ES, Eisenberger M, Carducci MA, Denmeade S, Levine M. 1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial. Annals of Oncology. Elsevier BV; 2023. p. S992–S992.